{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
LipoGel CR Base by Southeastern Medical Technologies
(2013)
Source URL:
First approved in 2013
Source:
LipoGel CR Base by Southeastern Medical Technologies
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M020
(2019)
Source URL:
First approved in 2013
Source:
B.S.C AMPUL by Cellcos Inc
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2013)
Source URL:
First approved in 2013
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2013)
Source URL:
First approved in 2013
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
SOMA Anti-Cancergen by SOMA Biotechnology Co., Ltd
(2013)
Source URL:
First approved in 2013
Source:
SOMA Anti-Cancergen by SOMA Biotechnology Co., Ltd
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2013
Source:
21 CFR 333D
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2013)
Source URL:
First approved in 2013
Source:
21 CFR 333D
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2018)
Source URL:
First approved in 2013
Source:
21 CFR 347
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2018)
Source URL:
First approved in 2013
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2014)
Source URL:
First approved in 2013
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE